Anemia is a frequent complication of cancer and its treatment. It produces many symptoms and significantly impairs metabolic and physiologic functions as well as patients' activity, well-being and quality of life. Life expectancy is also affected. This book, now being published in its second edition, comprehensively presents the current knowledge on anemia in cancer and its treatment with rhEPO. Future developments are also discussed. Based on updated and new chapters, including a broader spectrum of topics, outstanding international experts describe the scientific and clinical aspects of anemia in various fields of oncology and give diagnostic and therapeutic recommendations on when and how to use rhEPO. The book, considered as a standard work, will again serve as an essential source of information for radiotherapists, medical oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion and laboratory medicine, and pharmacologists.
Anemia, a frequent complication of cancer and its treatments, produces unwanted symptoms and significantly impairs metabolic and physiologic functions, as well as patients' activity, quality of life and even life expectancy. In its new Second Edition, this book presents current knowledge on anemia in cancer and its treatment with Recombinant Human Erythropoietin (rhEPO). Expanded, updated and newly added chapters describe scientific and clinical aspects of anemia, and give diagnostic and therapeutic recommendations on use of rhEPO. This is an essential source of information for radiotherapists, medical oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion and laboratory medicine, and pharmacologists.